The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Open accessAbstract
BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies. By altering the contractile mechanics of the cardiomyocyte, myosin inhibitors have the potential to modify pathophysiology and improve symptoms associated with HCM. OBJECTIVES: MAVERICK-HCM (Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) explored the safety and efficacy of mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, in nHCM. METHODS: The MAVERICK-HCM trial was a multicenter, double-blind, placebo-controlled, dose-ranging phase II study in adults with symptomatic nHCM (New York Heart Association functional class II/III), left ventricular ejection fraction (LVEF) ≥55%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥300 pg/ml. Participants were randomized 1:1:1 to mavacamten at a pharmacokinetic-adjusted dose (targeting plasma levels of 200 or 500 ng/ml), or placebo for 16 weeks, followed by an 8-week washout. Initial dose was 5 mg daily with 1 dose titration at week 6. RESULTS: Fifty-nine participants were randomized (19, 21, 19 patients to 200 ng/ml, 500 ng/ml, placebo, respectively). Their mean age was 54 years, and 58% were women. Serious adverse events occurred in 10% of participants on mavacamten and in 21% participants on placebo. Five participants on mavacamten had reversible reduction in LVEF ≤45%. NT-proBNP geometric mean decreased by 53% in the pooled mavacamten group versus 1% in the placebo group, with geometric mean differences of -435 and -6 pg/ml, respectively (p = 0.0005). Cardiac troponin I (cTnI) geometric mean decreased by 34% in the pooled mavacamten group versus a 4% increase in the placebo group, with geometric mean differences of -0.008 and 0.001 ng/ml, respectively (p = 0.009). CONCLUSIONS: Mavacamten, a novel myosin inhibitor, was well tolerated in most subjects with symptomatic nHCM. Furthermore, treatment was associated with a significant reduction in NT-proBNP and cTnI, suggesting improvement in myocardial wall stress. These results set the stage for future studies of mavacamten in this patient population using clinical parameters, including LVEF, to guide dosing. (A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy [MAVERICK-HCM]; NCT03442764).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
Self-citationHo, C. Y., Day, S. M., Ashley, E. A., Michels, M., Pereira, A. C., Jacoby, D., Cirino, A. L., Fox, J. C., Lakdawala, N. K., Ware, J. S., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033200 · Cited by 860
Self-citationA small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice
Green, E. M., Wakimoto, H., Anderson, R. L., Evanchik, M. J., Gorham, J. M., Harrison, B. C., Henze, M., Kawas, R., Oslob, J. D., Rodriguez, H. M., et al. (2016) · Science · doi:10.1126/science.aad3456 · Cited by 707
Moon, J. C. C., Reed, E., Sheppard, M. N., Elkington, A. G., Ho, S., Burke, M., Petrou, M., & Pennell, D. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.035 · Cited by 696
Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy
Ho, C. Y., López, B., Coelho-Filho, O. R., Lakdawala, N. K., Cirino, A. L., Jarolim, P., Kwong, R., González, A., Colan, S. D., Seidman, J. G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002659 · Cited by 696
Self-citationAdabag, A. S., Maron, B. J., Appelbaum, E., Harrigan, C. J., Buros, J. L., Gibson, C. M., Lesser, J. R., Hanna, C. A., Udelson, J. E., Manning, W. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.071 · Cited by 662
Maron, M. S., Maron, B. J., Harrigan, C., Buros, J., Gibson, C. M., Olivotto, I., Biller, L., Lesser, J. R., Udelson, J. E., Manning, W. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.006 · Cited by 503
Prognostic Value of LGE-CMR in HCM
Weng, Z., Yao, J., Chan, R. H., He, J., Yang, X., Zhou, Y., & He, Y. (2016) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2016.02.031 · Cited by 483
Prognostic Value of Late Gadolinium Enhancement in Clinical Outcomes for Hypertrophic Cardiomyopathy
Green, J. J., Berger, J. S., Kramer, C. M., & Salerno, M. (2012) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2011.11.021 · Cited by 452
Rubinshtein, R., Glockner, J. F., Ommen, S. R., Araoz, P. A., Ackerman, M. J., Sorajja, P., Bos, J. M., Tajik, A. J., Valeti, U. S., Nishimura, R. A., et al. (2010) · Circulation: Heart Failure · doi:10.1161/circheartfailure.109.854026 · Cited by 418
Anderson, R. L., Trivedi, D. V., Sarkar, S. S., Henze, M., Ma, W., Gong, H., Rogers, C. S., Gorham, J. M., Wong, F. L., Morck, M. M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809540115 · Cited by 405
Seferović, P. M., Polovina, M., Bauersachs, J., Arad, M., Ben Gal, T., Lund, L. H., Felix, S. B., Arbustini, E., Caforio, A. L. P., Farmakis, D., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1461 · Cited by 346
Maron, M. S., Rowin, E. J., Wessler, B. S., Mooney, P. J., Fatima, A., Patel, P., Koethe, B. C., Romashko, M., Link, M. S., & Maron, B. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1391 · Cited by 325
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial
Heitner, S. B., Jacoby, D., Lester, S. J., Owens, A., Wang, A., Zhang, D., Lambing, J., Lee, J., Semigran, M., & Sehnert, A. J. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3016 · Cited by 303
Self-citationCardiac Magnetic Resonance Detection of Myocardial Scarring in Hypertrophic Cardiomyopathy
Kwon, D. H., Smedira, N. G., Rodriguez, E. R., Tan, C., Setser, R., Thamilarasan, M., Lytle, B. W., Lever, H. M., & Desai, M. Y. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.026 · Cited by 249
Mentias, A., Raeisi-Giglou, P., Smedira, N. G., Feng, K., Sato, K., Wazni, O., Kanj, M., Flamm, S. D., Thamilarasan, M., Popovic, Z. B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.060 · Cited by 240
Kawas, R. F., Anderson, R. L., Ingle, S. R. B., Song, Y., Sran, A. S., & Rodriguez, H. M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776815 · Cited by 222
Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy
Maron, M. S., Rowin, E. J., Olivotto, I., Casey, S. A., Arretini, A., Tomberli, B., Garberich, R. F., Link, M. S., Chan, R. H. M., Lesser, J. R., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.023 · Cited by 209
Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy
Maron, B. J., Rowin, E. J., Udelson, J. E., & Maron, M. S. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.09.011 · Cited by 200
The role of super-relaxed myosin in skeletal and cardiac muscle
McNamara, J. W., Li, A., dos Remedios, C. G., & Cooke, R. (2015) · Biophysical Reviews · doi:10.1007/s12551-014-0151-5 · Cited by 175
Olivotto, I., Camici, P. G., Merlini, P. A., Rapezzi, C., Patten, M., Climent, V., Sinagra, G., Tomberli, B., Marín, F. R., Ehlermann, P., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004124 · Cited by 152
McNamara, J. W., Li, A., Smith, N. J., Lal, S., Graham, R. M., Kooiker, K. B., van Dijk, S. J., dos Remedios, C. G., Harris, S. P., & Cooke, R. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.03.009 · Cited by 147
B-Type Natriuretic Peptide and Survival in Hypertrophic Cardiomyopathy
Geske, J. B., McKie, P. M., Ommen, S. R., & Sorajja, P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.004 · Cited by 145
Significance of High-Sensitivity Cardiac Troponin T in Hypertrophic Cardiomyopathy
Kubo, T., Kitaoka, H., Yamanaka, S., Hirota, T., Baba, Y., Hayashi, K., Iiyama, T., Kumagai, N., Tanioka, K., Yamasaki, N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.055 · Cited by 142
Axelsson, A., Iversen, K. K., Vejlstrup, N. G., Ho, C. Y., Norsk, J. B., Langhoff, L., Ahtarovski, K. A., Corell, P., Havndrup, O., Jensen, M. K., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70241-4 · Cited by 138
Self-citationStern, J. A., Markova, S., Ueda, Y., Kim, J. B., Pascoe, P. J., Evanchik, M. J., Green, E. M., & Harris, S. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168407 · Cited by 135
Raja, A. A., Farhad, H., Valente, A. M., Couce, J.-P., Jefferies, J. L., Bundgaard, H., Zahka, K. G., Lever, H. M., Murphy, A. M., Ashley, E. A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032966 · Cited by 116
Self-citationLu, D., Pozios, I., Haileselassie, B., Ventoulis, I., Liu, H., Sorensen, L. L., Canepa, M., Phillip, S., Abraham, M. R., & Abraham, T. P. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.006657 · Cited by 112
Moreno, V., Hernández‐Romero, D., Vilchez, J. A., García‐Honrubia, A., Cambronero, F., Casas, T., González, J. M. R., Martínez, P., Climent, V. E., de la Morena, G., et al. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.07.245 · Cited by 96
COATS, C. J., Pavlou, M., Watkinson, O. T., Protonotarios, A., Moss, L., Hyland, R. A., Rantell, K. R., Pantazis, A. A., Tome, M., McKenna, W. J., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4847 · Cited by 84
High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
Seydelmann, N., Liu, D., Krämer, J., Drechsler, C., Hu, K., Nordbeck, P., Schneider, A., Störk, S., Bijnens, B. H., Ertl, G., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002839 · Cited by 82
Maron, M. S., Chan, R. H. M., Kapur, N. K., Jaffe, I. Z., McGraw, A. P., Kerur, R., Maron, B. J., & Udelson, J. E. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.02.025 · Cited by 82
Olivotto, I., Hellawell, J. L., Farzaneh‐Far, R., Blair, C. J., Coppini, R., MYERS, J. N., Belardinelli, L., & Maron, M. S. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002764 · Cited by 63
Mamidi, R., Li, J., Doh, C. Y., Verma, S., & Stelzer, J. E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009627 · Cited by 55
Functional effects of losartan in hypertrophic cardiomyopathy—a randomised clinical trial
Raja, A. A., Iversen, K. K., Vejlstrup, N. G., Ho, C. Y., Havndrup, O., Kofoed, K. F., Norsk, J. B., Jensen, M. K., & Bundgaard, H. (2015) · Heart · doi:10.1136/heartjnl-2015-308343 · Cited by 38
Self-citationdel Rio, C. L., Ueyama, Y., Baker, D. C., Dalton, S. R., Lucats, L., Janiak, P., Olivier, B., Lambing, J. L., Evanchik, M. J., & Green, E. M. (2017) · Circulation · Cited by 7
Cited by
Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31792-x · Cited by 1,296
Self-citationOmmen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.044 · Cited by 994
Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001250 · Cited by 807
Self-citation2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.045 · Cited by 643
Writing Committee Members, Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000937 · Cited by 605
Metadata
- Authors
- Ho, C. Y., Mealiffe, M. E., Bach, R. G., Bhattacharya, M., Choudhury, L., Edelberg, J. M., Hegde, S. M., Jacoby, D., Lakdawala, N. K., Lester, S. J., Ma, Y., Marian, A. J., Nagueh, S. F., Owens, A., Rader, F., Saberi, S., Sehnert, A. J., Sherrid, M. V., Solomon, S. D., Wang, A., Wever-Pinzon, O., Wong, T. C., & Heitner, S. B.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 75
- Issue
- 21
- Pages
- 2649-2660
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3028221850
- Cited by
- 355
- References
- 37
- FWCI
- 23.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.